Cheolwon Suh

1.2k citations
9 papers · 969 indexed · 1 hit paper · h-index 7

Cheolwon Suh

9 papers receiving 951 citations

Hit Papers

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemci...6112012202620162021200400600

Peers

Cheolwon Suh
Comparison fields: 5 of 50
  • Pulmonary and Respiratory Medicine 854
  • Oncology 664
  • Cancer Research 155
  • Radiology, Nuclear Medicine and Imaging 117
  • Molecular Biology 193
Replace DuyKhanh Pham with:
DuyKhanh Pham United States
Joan Lucca United States
Marco Angelo Burgio Italy
Anna Bettini Italy
José Rodrigues Pereira Brazil
Pil Gyu Hwang South Korea
Tejas Patil United States
S-H.I. Ou United States
Sayed M.S. Hashemi Netherlands
Johnathan Man Australia
Cheolwon Suh relative to DuyKhanh Pham United States DuyKhanh Pham's profile →
Citations per field
00.5×1.6×
DuyKhanh Pham · 1×
Citations per year

Countries citing papers authored by Cheolwon Suh

Since Specialization
Citations

This map shows the geographic impact of Cheolwon Suh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheolwon Suh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheolwon Suh more than expected).

Fields of papers citing papers by Cheolwon Suh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheolwon Suh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheolwon Suh. The network helps show where Cheolwon Suh may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Cheolwon Suh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Cheolwon Suh Line = papers co-authored together Cheolwon Suh links everyone, so they are left out of the graph.

All Works

9 of 9 papers shown
#Work
1 201918
2
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lungbreakdown →
2012611
3
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.
201113
4 2008125
5 2007152
6 200313
7 20031
8 20031
9 200235

About Cheolwon Suh

Cheolwon Suh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology, having authored 9 papers that have together received 969 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Diagnosis and Treatment (5 papers), Lung Cancer Research Studies (4 papers), Lymphoma Diagnosis and Treatment (2 papers), Acute Myeloid Leukemia Research (1 paper), Cancer Genomics and Diagnostics (1 paper), Medical Imaging Techniques and Applications (1 paper) and HIV/AIDS drug development and treatment (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (854 citations), Oncology (664 citations) and Cancer Research (155 citations). Cheolwon Suh has collaborated with scholars based in South Korea and Canada. Frequent co-authors include Sang‐We Kim, Dae Ho Lee, Jung‐Shin Lee, Keunchil Park, Jin Seok Ahn, Jae‐Won Lee, Myung‐Ju Ahn, Sung Jin Yoon, Hyae Young Kim and Jong Hee Han.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026